长期护理与养老院居民序贯异源二价新冠疫苗的体液与细胞免疫原性
加拿大安大略省长期护理与养老院居民在2022–2023年接种序贯异源二价新冠mRNA疫苗(BV1、BV2)后,体液与细胞免疫应答对祖先株高于Omicron变异株,但Omicron特异性中和抗体较单价疫苗增强;混合免疫提升体液应答;接种后4个月内IgG衰减,BV2后中和抗体与CD4+ T细胞应答未较BV1进一步衰减。
要点
- 二价疫苗接种诱导交叉反应抗体和T细胞应答,对祖先株高于Omicron变异株
- 混合免疫提升体液应答;BV2后Omicron BA.1中和抗体初期较BV1增高(男性尤著)
- 接种后4个月内抗Spike IgG衰减;BV2后中和抗体与CD4+ T细胞应答未见衰减
核心结论
- 两种异源二价疫苗接种后4个月内体液和细胞免疫应答不劣于单剂二价疫苗。
研究设计与样本
- COVID in Long-Term Care Study多站点观察性队列,纳入长期护理和养老院居民,评估BV1和BV2接种后7–120天的体液和细胞免疫原性。
主要发现
- 二价疫苗接种诱导交叉反应抗体和T细胞应答,对祖先SARS-CoV-2应答高于Omicron特异性变异株。
- 与单价疫苗接种相比,二价疫苗接种后Omicron特异性中和抗体增强。
- 混合免疫提升体液应答。
- BV2后Omicron BA.1中和抗体初期较BV1增高,尤其在男性;感染未暴露个体4个月内出现祖先中和抗体回升。
- BV2后对祖先Spike蛋白的CD4+ T细胞应答较BV1增强,尤其女性;Omicron BA.4/5和XBB.1.5中和抗体及T细胞应答在BV2与BV1后相似。
临床怎么用
- 在长期护理与养老院老年居民中,序贯异源二价新冠疫苗接种可诱导不劣于单剂二价疫苗的短期免疫应答。
- 需持续监测疫苗免疫原性,为脆弱老年人群的疫苗接种决策提供证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older adults were administered sequential heterogenous bivalent Ancestral/Omicron BA.1 and Ancestral/Omicron BA.4/5 SARS-CoV-2 mRNA vaccines in 2022-2023 in Ontario, Canada. Immunogenicity of this unique vaccination schedule was evaluated within the COVID in Long-Term Care Study, a multisite observational cohort of long-term care and retirement home residents. METHODS: Humoral and cellular immunogenicity were evaluated 7-120 days after vaccinations with first bivalent (Ancestral/Omicron BA.1; BV1) and second bivalent (Ancestral/Omicron BA.4/5; BV2) vaccines. Hybrid immunity and biological sex were considered, with measurements of anti-spike and anti-RBD (receptor binding domain) IgG and IgA antibodies by ELISA, live SARS-CoV-2 ancestral and Omicron BA.1, BA.5 and XBB.1.5 neutralizing antibodies by microneutralization assays, and T cell responses to ancestral and Omicron BA.1, BA.4/5, and XBB.1.5 spike proteins by activation-induced marker assays. RESULTS: Bivalent vaccination induced cross-reactive antibody and T cell responses. Higher responses were observed against ancestral SARS-CoV-2 than Omicron-specific variants, but Omicron-specific neutralizing antibodies were enhanced after bivalent vaccination compared to monovalent vaccination. Humoral responses were increased by hybrid immunity. Neutralizing antibodies against Omicron BA.1 were initially increased after BV2 compared to BV1 (especially in males), but in infection-naïve individuals there was back-boosting of ancestral neutralizing antibodies within 4 months. Enhanced CD4+ T cell responses to the ancestral spike protein were observed after BV2 compared to BV1 (particularly in females). Omicron BA.4/5 and XBB.1.5 neutralizing antibody and T cell responses were similar after BV2 and BV1. Waning of anti-SARS-CoV-2 IgG was observed after BV1 and BV2 within 4 months, and after BV1 but not BV2 for neutralizing antibodies and CD4+ T cell responses. CONCLUSIONS: Humoral and cellular immune responses after two heterogenous bivalent vaccines were noninferior to those after a single bivalent vaccine within four months of vaccination. Continued surveillance of vaccine immunogenicity is essential to inform evidence-based decisions on vaccination of vulnerable older adults.
引用
- Breznik JA, Ang JC, Bhakta H, et al. Humoral and cellular immunogenicity of sequential heterogeneous bivalent SARS-CoV-2 vaccinations in long-term care and retirement home residents. Vaccine. 2025. PMID: 41478237. doi:10.1016/j.vaccine.2025.128160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。